Stocknear Logo Stocknear
/
Popular
Login

Cohen & Steers Inc.

AI Score

XX

Unlock

81.08
0.39 (0.48%)
At close: Apr 02, 2025, 3:59 PM
82.10
1.25%
After-hours: Apr 02, 2025, 08:00 PM EDT
0.48%
Bid 77.84
Market Cap 4.13B
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) 2.97
PE Ratio (ttm) 27.3
Forward PE 24.55
Analyst Hold
Ask 84.15
Volume 81,131
Avg. Volume (20D) 217,078
Open 79.83
Previous Close 80.69
Day's Range 79.56 - 81.44
52-Week Range 64.13 - 110.67
Beta 1.52

About CNS

Cohen & Steers, Inc. is a publicly owned asset management holding company. Through its subsidiaries, the firm provides its services to institutional investors, including pension funds, endowments, and foundations. It manages separate client-focused equity, fixed income, multi-asset, and commodity portfolios through its subsidiaries. The firm launches and manages equity, fixed income, balanced, and multi-asset mutual funds through its subsidiaries...

[Read more]
Industry Asset Management
Sector Financial Services
IPO Date Aug 16, 2004
Employees 411
Stock Exchange NYSE
Ticker Symbol CNS
Website https://www.cohenandsteers.com
Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for CNS stock is "Hold." The 12-month stock price forecast is $106.5, which is an increase of 31.35% from the latest price.

Stock Forecasts

Next Earnings Release

Cohen & Steers Inc. is scheduled to release its earnings on Apr 16, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
1 week ago
+2.6%
Shares of financial stocks are trading higher amid... Unlock content with Pro Subscription
1 month ago
-3.55%
Shares of financial companies are trading lower amid President Trump's decision to implement tariffs, which may weigh on the economy, and decrease the likelihood of Fed rate hikes.
news image

1 day ago · accessnewswire.com

CNS Pharmaceuticals Reports Full Year 2024 Financial Results

Company has one year of cash to fund operations Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that is potentially blood brain barrier permeable with published clinical eff...

news image

1 week ago · benzinga.com

CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects

CNS Pharmaceuticals, Inc.  CNSP on Tuesday announced the primary analysis of its clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma Multiforme (GBM), an aggressive form of b...

news image

1 week ago · accessnewswire.com

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

Berubicin showed clinically relevant outcomes comparable to Lomustine across multiple endpoints, but not a statistically significant difference in overall survival, the primary endpoint. The safety pr...

news image

3 weeks ago · businesswire.com

Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of ...

news image

3 weeks ago · businesswire.com

Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Stifel 20...

news image

1 month ago · businesswire.com

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize...

news image

1 month ago · seekingalpha.com

31 Upcoming Dividend Increases, Including 3 Kings

This week sees 31 dividend increases, including three Dividend Kings: Genuine Parts, Commerce Bancshares, and Kimberly-Clark, showcasing impressive financial stability and growth. My investment strate...

news image

1 month ago · accessnewswire.com

CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing

Cash on hand provides over one year of runway to fund expected operations HOUSTON, TX / ACCESS Newswire / February 26, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopha...

news image

1 month ago · accessnewswire.com

CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum

Webcast presentation Wednesday, February 26th at 3:20 PM CET HOUSTON, TX / ACCESS Newswire / February 20, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical c...

news image

1 month ago · seekingalpha.com

Trumpflation Positions Cohen & Steers Poorly Due To Real Estate And Preferred Focus

Cohen & Steers (CNS) faces AUM declines due to asset depreciation in REITs and preferred shares amid persistent inflation affecting bond markets. This could be a portent for incoming outflows or inflo...

Create Price Alert on CNS

Your price alert will notify you when the stock price is above 81.08.

Add to Watchlist